Discovery of Precision Medicines and Chemical Probes for Cancer: Role of Proteomics and Genomics
Professor Paul Workman FRS FMedSci is Chief Executive and President of the Institute of Cancer Research, London and Harrap Professor of Pharmacology and Therapeutics. He was previously Director of the Cancer Research UK Cancer Therapeutics Unit at ICR – the largest non-profit cancer drug discovery group in the world. Workman has been instrumental in more than 20 new molecularly targeted anticancer drugs entering clinical trial. He is especially renowned for his innovative personal research in the discovery, chemical biology and molecular pharmacology of leading drugs acting on the molecular chaperone HSP90 (eg luminespib), PI3 kinase (eg pictilisib, GDC-0941) and protein kinases (gefitinib, capivasertib) and is the originator of the widely used Pharmacologic Audit Trail for biomarker-led drug development. Workman has published over 550 scientific publications, receiving over 43,000 citations, and has an h-index of 109. Workman has won numerous rewards and fellowships, including election to the Royal Society and the Academy of Medical Sciences. He was a scientific founder of Chroma Therapeutics and Piramed Pharma.
